{"filing":{"accession_number":"0001493152-26-026519","cik":"0001053369","ticker":"ELTP","company_name":"ELITE PHARMACEUTICALS INC /NV/","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/form8-k.htm"},"events":[{"id":7905,"run_id":6937,"accession_number":"0001493152-26-026519","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Elite Pharmaceuticals disclosed filing an Abbreviated New Drug Application (ANDA) with the FDA for a generic anticoagulant product via Item 7.01 Regulation FD Disclosure. While this is a significant regulatory milestone for a pharmaceutical company that could materially affect future revenue and competitive position, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or executive change). The ANDA filing represents material business development activity that would affect a reasonable investor's assessment of the company's pipeline and prospects.","company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":3291,"accession_number":"0001493152-26-026519","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Elite Pharmaceuticals disclosed filing an Abbreviated New Drug Application (ANDA) with the FDA for a generic anticoagulant product via Item 7.01 Regulation FD Disclosure. While this is a significant regulatory milestone for a pharmaceutical company that could materially affect future revenue and competitive position, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or executive change). The ANDA filing represents material business development activity that would affect a reasonable investor's assessment of the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:49:01.841962+00:00","company_name":"ELITE PHARMACEUTICALS INC /NV/","ticker":"ELTP","filing_date":"2026-06-01"}]}